Boehringer Ingelheim’s Cyltezo has a slight competitive edge over other concurrent biosimilar launches on certain key performance metrics, though prescriber...
According to Spherix Global Insights, US Rheumatologists are taking increasing ownership over lupus nephritis (LN) patient management, yet they are...
In the third annual patient chart analysis, major treatment shifts in biologic use and average daily steroid dose were observed....
U.S. specialists’ lack of satisfaction with current treatment options in cutaneous and discoid lupus paves the way for advanced pharmacological...
April 3, 2023 Skylar Jeremias Although rheumatologists, dermatologists, and gastroenterologists rated their awareness of adalimumab biosimilars as high, a significant...
Latest Saphnelo launch tracking data from Spherix showcases rheumatologists’ shifting perception on the drug’s steroid-sparing capabilities yet highlights access barriers...
Latest patient-level data analysis by Spherix Global Insights showcases year over year shifts in nephrology and rheumatology practice patterns alongside...
Newly released data may provide a competitive edge over in-class competitor, Janssen’s Tremfya EXTON, Pa., December 21, 2022 /PRNewswire/ — Spherix...
Surveyed EU5 rheumatologists indicate newfound shaky perceptions of the JAK class, though whether overall brand share and use will be...
Referrals from primary care physicians to rheumatologists are being delayed due to several factors EXTON, Pa., November 10, 2022 /PRNewswire/...
Expanded systemic lupus erythematosus (SLE) research in Europe reveals UK physicians perceive a higher unmet need and difficulty in treating...
IL-23 inhibitors and AbbVie’s Rinvoq are projected to have the largest growth in the coming months EXTON, Pa., October 13,...
